2024-11-01 18:25:57
Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab) is Safe and Well Tolerated in Phase IIa HBV Study
Corporate/ 2023-07-23
Subcutaneously Administered PD-L1 Antibo...

HANGZHOU and SHAOXING,China,Dec. 4,2020--Ascletis Pharma Inc. (HKEX:1672) announces today that Phase IIa data demonstrated that ASC22 (Envaf...

I Peace, Inc. Obtains IRB Approval for Production of Clinical and Research-Grade iPSCs for Commercial Use
Health/ 2023-07-22
I Peace, Inc. Obtains IRB Approval for P...

PALO ALTO,Calif.,Dec. 4,2020--I Peace,Inc.,a Palo Alto-based biotech start-up focusing on Nobel Prize-winning induced pluripotent stem cell ...

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release